Molecular pathways like PI3K/AKT/mTOR, activated in obese patients due to high circulating levels of IGF1, could be a potential therapeutic target in bladder cancer patients with high BMI (46). The gene discussed is MTOR; the disease is urinary bladder carcinoma.